Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that’s when a drug is prescribed for something it’s not FDA-approved for.

Top Alternatives to Ozempic That Are EffectiveReviewed by Dr. Craig Primack, MD, FACP, FAAP, FOMAOzempic is a medication approved by the FDA for individuals ...

Novo Nordisk dished out an up-front payment of $200 million (not to mention potential milestone payments of up to $1.8 billion) to acquire UBT251, a triple agonist -- that is, a medicine that ...

Novo Nordisk (NVO 1.20%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky 7% through 12:20 p.m. ET Tuesday after London's Financial Times reported ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building a stake in the Ozempic maker.

June 22 (Reuters) - Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other ...

Novo Nordisk’s Wegovy did around $8 billion in sales in 2024, in a market that is expected to grow to be worth $150 billion by 2030.

TD Cowen reiterated its Buy rating and $105.00 price target on Novo Nordisk (NYSE: NVO) Wednesday following meetings with the company’s senior leadership in Copenhagen. The pharmaceutical giant ...